Burden of Myelodysplastic Syndromes: A Literature Review of Epidemiological and Humanistic Aspects

References

[1] M. A. Sekeres, “The Myelodysplastic Syndromes,” Expert Opinion on Biological Therapy 7, no. 3 (2007): 369-377.

[2] R. Stauder, G.e Yu, K. A. Koinig, et al., “Health-Related Quality of Life in Lower-Risk MDS Patients Compared With Age- and Sex-Matched Reference Populations: A European LeukemiaNet Study,” Leukemia 32, no. 6 (2018): 1380-1392.

[3] M. Hoeks, T. Bagguley, R. Roelofs, et al., “Elevated Labile Plasma Iron (LPI) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated With Decreased Quality of Life and Reduced Survival,” Blood 132, no. Suppl 1 (2018): 4392.

[4] H. Wouters, B. Wolffenbuttel, G. Huls, et al., “The Anemia-Independent Effect of Myelodysplastic Syndromes on Health-Related Quality of Life,” HemaSphere 4, no. Suppl 1 (2020): 126-127.

[5] E. M. Gamper, F. Cottone, K. Sommer, et al., “The EORTC QLU-C10D Was More Efficient in Detecting Clinical Known Group Differences in Myelodysplastic Syndromes Than the EQ-5D-3L,” Journal of Clinical Epidemiology 137 (2021): 31-44.

[6] S. A. Ingber, K. Thompson, A. Lam, et al., “The Effects of Azacitidine on Quality of Life Measured Longitudinally in MDS Patients Treated at a Tertiary Care Center,” Blood 116, no. 21 (2010): 2571.

[7] A. Szende, C. Schaefer, T. F. Goss, et al., “Valuation of Transfusion-Free Living in MDS: Results of Health Utility Interviews With Patients,” Health and Quality of Life Outcomes 7 (2009): 81.

[8] C. R. Cogle, “Incidence and Burden of the Myelodysplastic Syndromes,” Current Hematologic Malignancy Reports 10, no. 3 (2015): 272-281.

[9] A. M. Zeidan, R. M. Shallis, R. Wang, et al., “Epidemiology of Myelodysplastic Syndromes: Why Characterizing the Beast Is a Prerequisite to Taming It,” Blood Reviews 34 (2019): 1-15.

[10] M. Shahzad, M. F. Khalid, A. Butt, et al., “Racial Disparities in Acute Myeloid Leukemia and Myelodysplastic Syndrome US FDA Drug Approval Trials,” Blood 142, no. Suppl 1 (2023): 7410.

[11] D. P. Lubeck, M. Danese, D. Jennifer, et al., “Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia,” Blood 128, no. 22 (2016): 5930.

[12] A. L. Bryant, S. W. Drier, S. Lee, et al., “A Systematic Review of Patient Reported Outcomes in Phase II or III Clinical Trials of Myelodysplastic Syndromes and Acute Myeloid Leukemia,” Leukemia Research 70 (2018): 106-116.

[13] E. N. Oliva, U. Platzbecker, P. Fenaux, et al., “Targeting Health-Related Quality of Life in Patients With Myelodysplastic Syndromes—Current Knowledge and Lessons to be Learned,” Blood Reviews 50 (2021): 100851.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.